Clinical Trials
Sponsor:
Sponsor Study ID:
Study Title:
A Multi center, Open label, Single arm Phase I Dose escalation and Phase II Dose expansion Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti tumor Activity of FCN 159 in Adult and Pediatric Participants With Neurofibromatosis Type 1
NCT Number:
NCT04954001
Phase:
I/II
Protocol Type:
Treatment
Age Group:
Adult and Children
Disease Sites:
Brain and Nervous System
Study Objectives:
FCN-159 is a highly active MEK1/2 inhibitor that was designed, synthesized and screened on the basis of the structure of trametinib. FCN-159 is an orally available and highly potent selective inhibitor of MEK1/2, which is expected to be a targeted therapy for the treatment of advanced solid tumors and neurofibromatosis type 1.
For more information about the trial above please contact the study team:
Trial opened at the following institutions: Medical University of South Carolina
Study Documents
(MUSC NetID required for document access)